Abecma Archives -

Bristol-Myers Squibb is on course to move its BCMA-targeting CAR-T therapy further up the treatment pathway in multiple

Abecma hits the mark in earlier-stage multiple myeloma

https://pharmaphorum.com/news/abecma-hits-the-mark-in-earlier-stage-multiple-myeloma/

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU

CHMP backs J&J’s myeloma CAR-T therapy Carvykti

https://pharmaphorum.com/news/chmp-backs-jjs-myeloma-car-t-therapy-carvykti/

Johnson & Johnson has secured a six-month FDA review for its multiple myeloma CAR-T therapy ciltacabtagene autoleucel (cilta-cel),

FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel

https://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/

The FDA has approved Bristol-Myers Squibb’s Abecma (idecabtagene vicleucel) for multiple myeloma, the first cell therapy to treat

FDA approves BMS’ multiple myeloma CAR-T Abecma

https://pharmaphorum.com/news/fda-approves-bms-multiple-myeloma-car-t-abecma/

Abecma